D284VRC Maximo II VR
Implantable Cardioverter Defibrillator (ICD)
D284VRC Maximo II VR

Device Survival Probability


    1 yr 2 yr 3 yr 4 yr 5 yr 6 yr 7 yr at 90.0 mo    
% Excluding Normal Battery Depletion 100.0 99.9 99.9 99.9 99.9 99.9 99.8 99.8    
% Including Normal Battery Depletion 99.8 99.6 99.4 99.2 98.7 97.9 94.9 91.8    
#   11178 10477 9637 8323 6555 4035 1333 211    
  • Including Normal Battery Depletion – This curve includes devices that have reached at least 80% of expected longevity. This curve is most representative of clinical performance and how long the device will last.
  • Excluding Normal Battery Depletion – This is the malfunction free survival curve.

Advisories For This Model

  • There are no advisories for this model.

Performance Notes For This Model

    • There are no performance notes for this model.

Product Characteristics

Generator Type ICD
Max. Delivered Energy 35 J
Connector Style Cx Style
Serial Number Prefix PZN
Mass 68 g
Volume 37 cc
Waveform Biphasic
Hide this content
Cx Style

Estimated Longevity

Charging Frequency 100% Pacing 50% Pacing 15% Pacing 100% Sensing
Monthly 4.3 4.7 4.9 5.0
Quarterly 6.7 7.5 8.1 8.4
Semi-annual 7.8 8.9 9.8 10.3

Longevity estimates based on the following device usage. Pacing Mode VVI; Ventricular Lower Pacing Rate 60ppm; Ventricular Pulse Width 0.4ms; Ventricular Pulse Amplitude 3V; Ventricle Impedance 510ohms; Ventricle Sensing Rate 70bpm; EGM prestorage OFF; Optivol ON; Charging frequency assumes maximum energy charge and includes therapy shocks and capacitor formation. Hide this content


EOS Indication

The Prolonged Service Period (PSP) is the time between the RRT and EOS. The PSP is defined as 3 months assuming the following conditions: 100% VVI pacing at 60 min-1, 2.5 V RV pacing amplitude; 0.4 ms pulse width; 600 Ω pacing load; and 6 full-energy charges. The EOS may be indicated before the end of 3 months if the device exceeds these conditions.


Distribution Data

US Market Release2008-09-17
CE Approval Date2008-03-14
Registered USA Implants12963
Estimated Active USA Implants8853
Normal Battery Depletions151
US Market Release2008-09-17
CE Approval Date2008-03-14
Estimated WW Distribution46911
Normal Battery Depletions168

Malfunctions (USA)

Therapy Function Not Compromised 13
Battery 3
Electrical Component 4
Possible Early Battery Depletion 3
Software/Firmware 3
Therapy Function Compromised 4
Battery 1
Electrical Component 2
Software/Firmware 1

Malfunctions (WW)

Therapy Function Not Compromised 29
Battery 6
Electrical Component 16
Possible Early Battery Depletion 3
Software/Firmware 4
Therapy Function Compromised 8
Battery 1
Electrical Component 5
Software/Firmware 2

Recommended Replacement (RRT)

Battery voltage less than or equal to 2.63V on 3 consecutive daily automatic measurements.


Charge Time


Data as of August 3, 2016

www.medtronic.com/productperformance 451050